Combined antifungal therapy against systemic murine infections by rare Cryptococcus species

Pamela Thomson, Emilio Mayayo, Loida López-Fernández, Josep Guarro, Javier Capilla

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

3 Citas (Scopus)

Resumen

Cryptococcus albidus and Cryptococcus laurentii are uncommon species of this genus that in recent decades have increasingly caused opportunistic infections in humans, mainly in immunocompromised patients; the best therapy for such infection being unknown. Using a murine model of systemic infection by these fungi, we have evaluated the efficacy of amphotericin B (AMB) at 0.8 mg/kg, administered intravenously, fluconazole (FLC) or voriconazole (VRC), both administered orally, at 25 mg/kg and the combination of AMB plus VRC against three C. albidus and two C. laurentii strains. All the treatments significantly reduced the fungal burden in all the organs studied. The combination showed a synergistic effect in the reduction in fungal load, working better than both monotherapies. The histopathological study confirmed the efficacy of the treatments.

Idioma originalInglés
Páginas (desde-hasta)112-117
Número de páginas6
PublicaciónMycoses
Volumen60
N.º2
DOI
EstadoPublicada - 1 feb 2017
Publicado de forma externa

Áreas temáticas de ASJC Scopus

  • Dermatología
  • Enfermedades infecciosas

Huella Profundice en los temas de investigación de 'Combined antifungal therapy against systemic murine infections by rare Cryptococcus species'. En conjunto forman una huella única.

Citar esto